Globe Newswire07.13.18
Stereotaxis Inc., the global leader in robotic technologies for cardiac arrhythmia treatment, has appointed Ross B. Levin to its Board of Directors. Levin is the director of research at Arbiter Partners, a New York-based investment fund and shareholder of Stereotaxis. Levin serves on the Board of Directors for Capital Senior Living Corporation and is vice chairman of the Cerebral Palsy Associations of New York State.
“Stereotaxis has the potential to transform endovascular medicine and improve patient care,” said Levin. “I am excited to join the board and look forward to actively contributing to the effort to build a highly successful and impactful company.”
Concurrent with the appointment of Levin, Stereotaxis also announced that Fred A. Middleton is retiring from the board. Middleton and Sanderling Ventures were among the first institutional investors in Stereotaxis and Middleton has served on the board since the company’s earliest days as a startup. “I have enjoyed my time helping Stereotaxis grow from a promising new technology to a global company with clinically and commercially validated surgical robotic systems in cardiology that have successfully treated over 100,000 patients to date,” commented Middleton. “I am also encouraged by the commitment of Stereotaxis’ management and investors to the continued innovation of the company’s technology platform, which I believe should create a path for greater clinical adoption and growth.”
Board Chairman and CEO David Fischel, said, “We appreciate Fred’s many contributions over the years in nurturing and supporting Stereotaxis’ progress. We are excited to have Ross join the board.”
Stereotaxis is the global leader in robotic technologies designed to enhance arrhythmia treatment and performance of endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.
“Stereotaxis has the potential to transform endovascular medicine and improve patient care,” said Levin. “I am excited to join the board and look forward to actively contributing to the effort to build a highly successful and impactful company.”
Concurrent with the appointment of Levin, Stereotaxis also announced that Fred A. Middleton is retiring from the board. Middleton and Sanderling Ventures were among the first institutional investors in Stereotaxis and Middleton has served on the board since the company’s earliest days as a startup. “I have enjoyed my time helping Stereotaxis grow from a promising new technology to a global company with clinically and commercially validated surgical robotic systems in cardiology that have successfully treated over 100,000 patients to date,” commented Middleton. “I am also encouraged by the commitment of Stereotaxis’ management and investors to the continued innovation of the company’s technology platform, which I believe should create a path for greater clinical adoption and growth.”
Board Chairman and CEO David Fischel, said, “We appreciate Fred’s many contributions over the years in nurturing and supporting Stereotaxis’ progress. We are excited to have Ross join the board.”
Stereotaxis is the global leader in robotic technologies designed to enhance arrhythmia treatment and performance of endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.